Journals / Kulak Burun Boğaz ve Baş Boyun Cerrahisi / 2021 / Cilt: 29 - Sayı: 3

Current Approaches to Ototoxicity

Ototoksisitede Güncel Yaklaşım

Pages
210–221
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, ototoxicity is discussed in detail in line with these considerations, and drugs that cause ototoxicity, protective agents, and related animal studies are examined.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ototoxicity is the damage to the cochlear and vestibular organs as a result of exposure to various therapeutic agents and chemicals (organic solvents, asphyxiant gases, pesticides, heavy metals, and environmental chemicals).
📊
Key Findings & Data:The prevalence of ototoxicity in all age groups varies between 4% and 90%.
💡
Conclusion & Impact:In this review, ototoxicity is discussed in detail in line with these considerations, and drugs that cause ototoxicity, protective agents, and related animal studies are examined.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Ototoxicity is the damage to the cochlear and vestibular organs as a result of exposure to various therapeutic agents and chemicals (organic solvents, asphyxiant gases, pesticides, heavy metals, and environmental chemicals). Agents known to cause ototoxicity are antibiotics, antineoplastic agents, diuretics, and anti-inflammatory, antimalarial, and ototopical drugs. Ototoxicity causes damage to the outer hair cells in the organ of corti and the type I hair cells in the vestibular system. The most common ototoxicity symptoms are tinnitus, hearing loss, dizziness, hyperacusis, and auditory saturation. The prevalence and degree of ototoxicity may manifest differently in each person. These individual differences result from the difference in genetic susceptibility to the ototoxic effects of the treatment. The prevalence of ototoxicity in all age groups varies between 4% and 90%. Although ototoxicity is not a life-threatening condition, it can have a negative impact on communication and health-related quality of life, affecting important professional, educational, and social outcomes. Even though there is no widely accepted protocol, an effective ototoxicity monitoring program should include a protocol that includes pure tone audiometry, a basic audiological test battery for otoacoustic emission and immittance meter, and appropriate follow-up tests. Various treatment methods and protective agents are used to minimize the damage caused by ototoxicity. In addition, many animal studies are carried out to prevent ototoxicity. In this review, ototoxicity is discussed in detail in line with these considerations, and drugs that cause ototoxicity, protective agents, and related animal studies are examined.

Özet

Ototoksisite çeşitli terapötik ajanlar ve kimyasal maddelerle (organikçözücüler, boğucu gazlar, böcek ilaçları, ağır metaller, çevreselkimyasallar) karşılaşma sonucu koklear ve vestibüler organlarda oluşanhasarlanmadır. Ototoksisiteye neden olduğu bilinen ajanlar, antibiyotikler,antineoplastikler, diüretikler, antiinflamatuar, antimalaryal ilaçlarve ototopik ilaçlardır. Ototoksisite, korti organında bulunan dış şaçlıhücrelerde ve vestibüler sistemde bulunan Tip 1 tüy hücrelerinde hasarayol açar. Ototoksisite en fazla görülen semptomlar; tinnitus, işitmekaybı, baş dönmesi, hiperakuzi ve işitsel dolgunluktur. Ototoksisiteprevalansı ve derecesi, kişisel farklılıklar gösterebilir. Bu kişisel farklılıklar,tedavi¬nin ototoksik etkilerine genetik duyarlılık farkından kaynaklanır.Tüm yaş gruplarındaki ototoksisite pre¬valansı %4-90arasında değişir. Ototoksisite, yaşamı tehdit eden bir durum olmasa daönemli mesleki, eğitimsel ve sosyal sonuçlarla iletişim ve sağlıkla ilişkiliyaşam kalitesi üzerinde olumsuz bir etkisi olabilir. Etkili bir ototoksisiteizleme programı; saf ses odyometrisi, otoakustik emisyon veimmitansmetrik değerlendirme yapan temel odyolojik test bataryası veuygun takip testlerini içeren bir protokolü içermelidir, ancak yaygınolarak kabul edilen bir protokol bulunmamaktadır. Ototoksisitenin sonucumeydana gelen hasarı en aza indirmek için çeşitli tedavi yöntemlerive koruyucu ajanlar kullanılmaktadır. Bunun yanı sıraototoksisitenin önlenmesi adına çok sayıda hayvan çalışması yapılmaktadır.Bu bilgiler doğrultusunda hazırlamış olduğumuz bu derlemede,ototoksisite ayrıntılı şekilde ele alınmış olup, ototoksisiteyeneden olan ilaçlar, koruyucu ajanlar ve bununla ilgili olarak yapılanhayvan çalışmaları incelenmiştir.

🔖

Cite This Article

ÇULHAOĞLU, B., ÖZER, F., AYDIN, B. D., DEMİRÖZ, G. B., ÇAĞLAR, T. G., KÜÇÜKÖNER, Ö., ERBEK, S. (2021). Current Approaches to Ototoxicity. Kulak Burun Boğaz ve Baş Boyun Cerrahisi, Cilt: 29 - Sayı: 3, 210–221. https://ajindex.com/articles/346862

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Morata TC. Chemical exposure as a risk factor for hearing loss. J Occup Environ Med. 2003;45(7):676-82. [Crossref] 2. Chiodo AA, Alberti PW. Experimental, clinical and preventive aspects of ototoxicity. Eur Arch Otorhinolaryngol. 1994;251(7):375-92. [Crossref] [PubMed] 3. Chen Y, Huang WG, Zha DJ, Qiu JH, Wang JL, Sha SH, et al. Aspirin attenuates gentamicin ototoxicity: from the laboratory to the clinic. Hear Res. 2007;226(1-2):178-82. [Crossref] [PubMed] 4. Hain TC, Cherchi M, Yacovino DA. Bilateral vestibular loss. Semin Neurol. 2013;33(3): 195-203. [Crossref] [PubMed] 5. Ganesan P, Schmiedge J, Manchaiah V, Swapna S, Dhandayutham S, Kothandaraman PP. Ototoxicity: a challenge in diagnosis and treatment. J Audiol Otol. 2018;22(2):59-68. [Crossref] [PubMed] [PMC] 6. Landier W. Ototoxicity and cancer therapy. Cancer. 2016;1;122(11):1647-58. [Crossref] [PubMed] 7. Schmitt NC, Page BR. Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients. Int J Audiol. 2018;57(sup4):S49-S54. [Crossref] [PubMed] [PMC] 8. Lord SG. Monitoring protocols for cochlear toxicity. Semin Hear. 2019;40(2):122-43. [Crossref] [PubMed] [PMC] 9. Henley CM, Rybak LP. Developmental ototoxicity. Otolaryngol Clin North Am. 1993;26(5):857-71. [Crossref] [PubMed] 10. Konrad-Martin D, Gordon JS, Reavis KM, Wilmington DJ, Helt WJ, Fausti SA. Audiological monitoring of patients receiving ototoxic drugs. Perspectives on Hearing and Hearing Disorders Research and Diagnostics. 2005;9(1):17-22. [Crossref] 11. Campbell KC, Kalkanis J, Glatz FR. Ototoxicity: mechanisms, protective agents, and monitoring. Current Opinion in Otolaryngology & Head and Neck Surgery. 2000;8(5):436-40. [Crossref] 12. Leigh-Paffenroth E, Reavis KM, Gordon JS, Dunckley KT, Fausti SA, Konrad-Martin D. Objective measures of ototoxicity. Perspectives on Hearing and Hearing Disorders Research and Diagnostics. 2005;9(1):10-6. [Crossref] 13. Brooks B, Knight K. Ototoxicity monitoring in children treated with platinum chemotherapy. Int J Audiol. 2018;57(sup4):S34-S40. [Crossref] [PubMed] 14. Handelsman JA. Vestibulotoxicity: strategies for clinical diagnosis and rehabilitation. Int J Audiol. 2018;57(sup4):S99-S107. [Crossref] [PubMed] 15. Konrad-Martin D, Reavis KM, McMillan G, Helt WJ, Dille M. Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA). J Rehabil Res Dev. 2014;51(1): 81-100. [Crossref] [PubMed] [PMC] 16. McGuire JM, Bunch RL, Anderson RC, Boaz HE, Flyn